Developing and validating a short version of the multidimensional depression scale in asian adolescents sample using rasch analysis. [PDF]
Cheung HN, Wong CC, Ho WS, Chan SCY.
europepmc +1 more source
Phase‐Change Solvents for Thermally Switchable Ion Conduction in Organogels
Organogels containing salts dissolved in phase‐change solvents exhibit thermally switchable ion conduction. The organogels, which display an over 10 000‐fold on‐off ratio and high cycling stability, can be synthesized with a wide range of salts and customizable conductivity/temperature relations for applications in ionotronics and energy storage ...
Yi‐ming Yuan, Thomas B. H. Schroeder
wiley +1 more source
Assessment of unconfined compressive strength of nano-doped fly ash-treated clayey soil using machine learning tools. [PDF]
Kumar A, Sinha S, Pradhananga R.
europepmc +1 more source
Series of Almost Monotonicity and Alternating Series Rearrangement
诗游 林
openalex +1 more source
Norbornene‐based copolymers with tunable n‐alkyl pendant length provide control over matrix free volume, enabling elastomeric materials via frontal ring‐opening metathesis polymerization (FROMP). ABSTRACT Frontal ring‐opening metathesis polymerization (FROMP) enables rapid, energy‐efficient access to high‐performance thermosets and thermoplastics, but ...
Kevin A. Stewart +4 more
wiley +1 more source
Improved Heinz inequalities via the Jensen functional
Krnić Mario, Pečarić Josip
doaj +1 more source
A non-monotonic code for event probability in the human brain. [PDF]
Foucault C +5 more
europepmc +1 more source
Meissner Effect and Nonreciprocal Charge Transport in Non‐Topological 1T‐CrTe2/FeTe Heterostructures
This work demonstrates interface‐induced superconductivity (Tc ∼12 K) with a robust Meissner effect and pronounced nonreciprocal transport in epitaxial 1T‐CrTe2/FeTe heterostructures, where 1T‐CrTe2 is a 2D ferromagnet, and FeTe is an antiferromagnetic metal.
Zi‐Jie Yan +13 more
wiley +1 more source
Improving Maximum Tolerated Dose Selection in Model-Assisted Designs for Phase I Trials Through Bayesian Dose-Response Model. [PDF]
Wakayama R, Momozaki T, Ando S.
europepmc +1 more source

